Abstract
The existing pharmacophore models for σ1 receptor ligands are summarized. A common feature of these models is a basic amino group surrounded by different hydrophobic structural elements. The development of novel spirocyclic σ1 receptor ligands (e.g. 3, 4) is based on these models. Enlargement of the distance between the basic amino group and the “Primary Hydrophobic Region ” by attachment of the amino group at the cyclohexane ring (9, 10) did not lead to increased σ1 affinity. However, introduction of an additional aryl moiety (12, 17) resulted in very potent σ1 receptor ligands. The high affinity of these compounds is explained by interaction of the additional aryl moiety with a previously unrecognized hydrophobic pocket of the σ1 receptor protein. The promising σ1 affinity and selectivity of the spirocyclic piperidine 3 led to the fluorinated PET-tracers [18F]18 and [18F]19 with excellent σ1 receptor affinity, receptor selectivity, pharmacokinetic and neuroimaging properties.
Keywords: σ1 receptor ligands, σ1 pharmacophore models, spirocyclic σ1 ligands, structure -σ1 affinity, relationships, pyrazole bioisosteres, thiophene bioisosteres, C-H-bond arylation, fluorinated PET-tracer, cyclohexane ring, neuroimaging properties
Current Pharmaceutical Design
Title: Pharmacophore Models and Development of Spirocyclic Ligands for σ1 Receptors
Volume: 18 Issue: 7
Author(s): Bernhard Wunsch
Affiliation:
Keywords: σ1 receptor ligands, σ1 pharmacophore models, spirocyclic σ1 ligands, structure -σ1 affinity, relationships, pyrazole bioisosteres, thiophene bioisosteres, C-H-bond arylation, fluorinated PET-tracer, cyclohexane ring, neuroimaging properties
Abstract: The existing pharmacophore models for σ1 receptor ligands are summarized. A common feature of these models is a basic amino group surrounded by different hydrophobic structural elements. The development of novel spirocyclic σ1 receptor ligands (e.g. 3, 4) is based on these models. Enlargement of the distance between the basic amino group and the “Primary Hydrophobic Region ” by attachment of the amino group at the cyclohexane ring (9, 10) did not lead to increased σ1 affinity. However, introduction of an additional aryl moiety (12, 17) resulted in very potent σ1 receptor ligands. The high affinity of these compounds is explained by interaction of the additional aryl moiety with a previously unrecognized hydrophobic pocket of the σ1 receptor protein. The promising σ1 affinity and selectivity of the spirocyclic piperidine 3 led to the fluorinated PET-tracers [18F]18 and [18F]19 with excellent σ1 receptor affinity, receptor selectivity, pharmacokinetic and neuroimaging properties.
Export Options
About this article
Cite this article as:
Wunsch Bernhard, Pharmacophore Models and Development of Spirocyclic Ligands for σ1 Receptors, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436548
DOI https://dx.doi.org/10.2174/138161212799436548 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Model Systems for Pulmonary Infectious Diseases: Paradigms of Anthrax and Tuberculosis
Current Topics in Medicinal Chemistry Anthocyanins as a Potential Therapy for Diabetic Retinopathy
Current Medicinal Chemistry Mechanisms of Colon Cancer Prevention with and Beyond COX-2 Inhibition
Current Topics in Medicinal Chemistry Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology 18F-fluoro-deoxy-D-glucose PET/CT in Establishing the Relationship Between the Metabolic Activity of Aorta and Iliac Artery Aneurysms in Cancer Patients
Current Medical Imaging HDAC Inhibitor Sodium Butyrate Augments the MEF2C Enhancement of Nampt Expression under Hypoxia
Current Pharmaceutical Design Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Current Medicinal Chemistry Releasing of Herpes Simplex Virus Carrying NGF in Subarachnoid Space Promotes the Functional Repair in Spinal Cord Injured Rats
Current Gene Therapy Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Extracts of Bacopa monnieri (L) Pennell Down-Regulate the Expression of Leukotriene C<sub>4</sub> Synthase mRNA in HL-60 Cells and Suppress OVAInduced Inflammation in BALB/c Mice
Current Bioactive Compounds The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry Editorial:Tubulin-targeted Cancer Chemotherapeutics: Advances and Challenges
Current Topics in Medicinal Chemistry New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design Tocotrienols Target PI3K/Akt Signaling in Anti-Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle Delivery Systems for DNA/RNA and their Potential Applications in Nanomedicine
Current Topics in Medicinal Chemistry Biodegradable Nanoparticles: A Recent Approach and Applications
Current Drug Targets Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Effects of Nanosuspension Formulations on Transport, Pharmacokinetics, In Vivo Targeting and Efficacy for Poorly Water-soluble Drugs
Current Pharmaceutical Design Anti-Angiogenic Agents and Cancer: Current Insights and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery